The siRNA cocktail targeting interleukin 10 receptor and transforming growth factor-β receptor on dendritic cells potentiates tumour antigen-specific CD8+ T cell immunity

Clinical and Experimental Immunology

Volumn 181, Issue 1, 2015, Pages 164-178

  Ahn, Y H ^a   Hong, S O ^a   Kim, J H ^a   Noh, K H ^a,b   Song, K H ^a   Lee, Y H ^a   Jeon, J H ^c   Kim, D W ^d   Seo, J H ^a   Kim, T W ^a  

^a Korea University College of Medicine   (South Korea)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c University of Texas M D Anderson Cancer Center ^*  (South Korea)

^d Seoul National University College of Medicine   (South Korea)

Author keywords

Dendritic cell; IL 10RA; Immunotherapy; SiRNA; TGF

Indexed keywords

BIM PROTEIN; INTERLEUKIN 10; INTERLEUKIN 10 RECEPTOR; INTERLEUKIN 10 RECEPTOR ALPHA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; APOPTOSIS REGULATORY PROTEIN; BCL-2-LIKE PROTEIN 11; MEMBRANE PROTEIN; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; PROTEIN E7; PTEN PROTEIN, MOUSE; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW DERIVED DENDRITIC CELL; CANCER MODEL; CD8+ T LYMPHOCYTE; CELL SELECTION; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; GENE SILENCING; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOPOTENTIATION; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; UTERINE CERVIX CANCER; ANIMAL; C57BL MOUSE; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; METABOLISM; PROCEDURES; RNA INTERFERENCE; TUMOR CELL LINE; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

ANIMALS; ANTIGENS, NEOPLASM; APOPTOSIS REGULATORY PROTEINS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DENDRITIC CELLS; FEMALE; HUMAN PAPILLOMAVIRUS 16; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; PAPILLOMAVIRUS E7 PROTEINS; PROTO-ONCOGENE PROTEINS; PTEN PHOSPHOHYDROLASE; RECEPTORS, INTERLEUKIN-10; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSFORMING GROWTH FACTOR BETA; UTERINE CERVICAL NEOPLASMS;

EID: 84930418638     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12620     Document Type: Article

References (41)

1. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med 2004; 10:475-80.
2. Gilboa E. DC-based cancer vaccines. J Clin Invest 2007; 117:1195-203.
3. Kobie JJ, Wu RS, Kurt RA et al. Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines. Cancer Res 2003; 63:1860-4.
4. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005; 5:296-306.
5. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005; 5:263-74.
6. Muller AJ, Scherle PA. Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. Nat Rev Cancer 2006; 6:613-25.
7. Goh C, Narayanan S, Hahn YS. Myeloid-derived suppressor cells: the dark knight or the joker in viral infections? Immunol Rev 2013; 255:210-21.
8. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 2004; 4:941-52.
9. Chen L, Qiu M, He W, Huang A, Liu J. Functional study of immature dendritic cells co-transfected with IL-10 and TGF-beta 1 genes in vitro. Mol Biol Rep 2012; 39:6633-9.
10. Wojtowicz-Praga S. Reversal of tumor-induced immunosuppression by TGF-beta inhibitors. Invest New Drugs 2003; 21:21-32.
11. Sato K, Kawasaki H, Nagayama H et al. TGF-beta 1 reciprocally controls chemotaxis of human peripheral blood monocyte-derived dendritic cells via chemokine receptors. J Immunol 2000; 164:2285-95.
12. Kubo M, Hanada T, Yoshimura A. Suppressors of cytokine signaling and immunity. Nat Immunol 2003; 4:1169-76.
13. Rauh MJ, Sly LM, Kalesnikoff J et al. The role of SHIP1 in macrophage programming and activation. Biochem Soc Trans 2004; 32:785-8.
14. Turnis ME, Song XT, Bear A et al. IRAK-M removal counteracts dendritic cell vaccine deficits in migration and longevity. J Immunol 2010; 185:4223-32.
15. Zhang J, Yu J, Yang L et al. Enhanced activation of human dendritic cells by silencing SOCS1 and activating TLRs simultaneously. Cancer Immunol Immunother 2012; 61:1653-61.
16. Lin KY, Guarnieri FG, Staveley-O'Carroll KF et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996; 56:21-6.
17. Wu TC. The role of vascular cell adhesion molecule-1 in tumor immune evasion. Cancer Res 2007; 67:6003-6.
18. Wu TC, Guarnieri FG, Staveley-O'Carroll KF et al. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci USA 1995; 92:11671-5.
19. Kang TH, Lee JH, Noh KH et al. Enhancing dendritic cell vaccine potency by combining a BAK/BAX siRNA-mediated antiapoptotic strategy to prolong dendritic cell life with an intracellular strategy to target antigen to lysosomal compartments. Int J Cancer 2007; 120:1696-703.
20. Kim JH, Kang TH, Noh KH et al. Enhancement of dendritic cell-based vaccine potency by anti-apoptotic siRNAs targeting key pro-apoptotic proteins in cytotoxic CD8(+) T cell-mediated cell death. Immunol Lett 2009; 122:58-67.
21. Kim JH, Kang TH, Noh KH et al. Enhancement of DC vaccine potency by activating the PI3K/AKT pathway with a small interfering RNA targeting PTEN. Immunol Lett 2010; 134:47-54.
22. Kim JH, Kang TH, Noh KH et al. Blocking the immunosuppressive axis with small interfering RNA targeting interleukin (IL)-10 receptor enhances dendritic cell-based vaccine potency. Clin Exp Immunol 2011; 165:180-9.
23. Kim TW, Hung CF, Ling M et al. Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J Clin Invest 2003; 112:109-17.
24. Kim TW, Lee JH, He L et al. Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency. Cancer Res 2005; 65:309-16.
25. Ley R, Balmanno K, Hadfield K, Weston C, Cook SJ. Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. J Biol Chem 2003; 278:18811-6.
26. Qi XJ, Wildey GM, Howe PH. Evidence that Ser87 of BimEL is phosphorylated by Akt and regulates BimEL apoptotic function. J Biol Chem 2006; 281:813-23.
27. Lu J, Quearry B, Harada H. p38-MAP kinase activation followed by BIM induction is essential for glucocorticoid-induced apoptosis in lymphoblastic leukemia cells. FEBS Lett 2006; 580:3539-44.
28. Luciano F, Jacquel A, Colosetti P et al. Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene 2003; 22:6785-93.
29. Zhu J, Paul WE. CD4 T cells: fates, functions, and faults. Blood 2008; 112:1557-69.
30. O'Garra A, Hosken N, Macatonia S, Wenner CA, Murphy K. The role of macrophage- and dendritic cell-derived IL12 in Th1 phenotype development. Res Immunol 1995; 146:466-72.
31. Banchereau J, Pulendran B, Steinman R, Palucka K. Will the making of plasmacytoid dendritic cells in vitro help unravel their mysteries? J Exp Med 2000; 192:F39-44.
32. Stoitzner P, Green LK, Jung JY et al. Inefficient presentation of tumor-derived antigen by tumor-infiltrating dendritic cells. Cancer Immunol Immunother 2008; 57:1665-73.
33. Perrot I, Blanchard D, Freymond N et al. Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage. J Immunol 2007; 178:2763-9.
34. Gigante M, Blasi A, Loverre A et al. Dysfunctional DC subsets in RCC patients: ex vivo correction to yield an effective anti-cancer vaccine. Mol Immunol 2009; 46:893-901.
35. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391:806-11.
36. Zamore PD, Tuschl T, Sharp PA, Bartel DP. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 2000; 101:25-33.
37. Ge Q, Xu JJ, Evans DM, Mixson AJ, Yang HY, Lu PY. Leveraging therapeutic potential of multi-targeted siRNA inhibitors. Future Med Chem 2009; 1:1671-81.
38. Ashley CE, Carnes EC, Phillips GK et al. The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers. Nat Mater 2011; 10:389-97.
39. Liu K, Chen H, You Q, Shi H, Wang Z. The siRNA cocktail targeting VEGF and HER2 inhibition on the proliferation and induced apoptosis of gastric cancer cell. Mol Cell Biochem 2014; 386:117-24.
40. Weber F, Byrne SN, Le S et al. Transforming growth factor-beta1 immobilises dendritic cells within skin tumours and facilitates tumour escape from the immune system. Cancer Immunol Immunother 2005; 54:898-906.
41. Halliday GM, Le S. Transforming growth factor-beta produced by progressor tumors inhibits, while IL-10 produced by regressor tumors enhances, Langerhans cell migration from skin. Int Immunol 2001; 13:1147-54.